• RxStrategies Clinical Insights — November Issue 1

    Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the… Read more »

  • RxStrategies, Inc. Names Skip Devanny Chief Revenue Officer

    BOCA RATON, Fla., October 28, 2015—RxStrategies, Inc. (www.rxstrategies.com) is pleased to announce the appointment of Skip Devanny to the position of Chief Revenue Officer. In this new role, Skip joins the RxStrategies’ senior leadership team and has responsibility for sales and marketing including the delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I… Read more »

  • RxStrategies Clinical Insights — October Issue 1

    Welcome to the first October edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Tresiba® (insulin degludec injection) September 25, 2015 — The U.S. Food and Drug Administration approved Tresiba® (insulin degludec injection) and Ryzodeg® 70/30 (insulin degludec/insulin… Read more »

  • RxStrategies Clinical Insights — September 2015 Issue 1

    Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with… Read more »

  • September 340B Insider

    Welcome to the September edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   RxStrategies’ Perspective: Proposed Mega Reg Guidance As you know, the Health Resources and Services Administration (HRSA) released on August 28, the provisions of the 340B Drug Pricing Program Omnibus Guidance (Proposed Guidance). The Proposed Guidance… Read more »

  • RxStrategies Travels the Country in 2015

    So far this year, the RxStrategies team has traveled from San Francisco to Washington D.C.—with many stops in between—to share the latest developments on the 340B drug discount program. Throughout the rest of the year, we will be attending and presenting at conferences in Florida, Alabama, Alaska, Georgia, California and New Orleans. Aug. 21-25 RxStrategies… Read more »

  • August 340B Insider

    Welcome to the August edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B RECERTIFICATION REMINDER   Recertification Deadline September 9    340B Health sent a reminder to Covered Entities (CEs) regarding the Sept. 9 deadline to recertify information in the 340B program database. It is vital to… Read more »

  • RxStrategies, Inc. Names Rhodie Smith National Sales Manager

    BOCA RATON, Florida, September 4, 2014-RxStrategies, Inc. is pleased to announce the appointment of Rhodie Smith to National Sales Manager. In this new role, Rhodie joins the RxStrategies’ senior leadership team and is responsible for sales and delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I am very… Read more »

  • RxS UPDATES: RxStrategies Web Portal Update

    In our continuing commitment to provide usable tools and resources, the RxStrategies IT team has updated the web portal to include order status for all replenishment drugs. It is now possible to review all orders placed and the disposition of them in real-time. If you have not yet utilized the web portal and are in… Read more »